gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
gptkbp:administered_by
|
intravenous infusion
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
gptkbp:bioavailability
|
gptkb:trastuzumab-dkst
gptkb:trastuzumab-pkrb
gptkb:trastuzumab-qyzy
|
gptkbp:can_be_combined_with
|
gptkb:docetaxel
gptkb:pertuzumab
gptkb:carboplatin
chemotherapy
|
gptkbp:chemical_formula
|
C6475 H10000 N1715 O2100 S44
|
gptkbp:clinical_trial
|
Phase III
|
gptkbp:contraindication
|
pregnancy
lactation
hypersensitivity to trastuzumab
|
gptkbp:developed_by
|
gptkb:Genentech
|
gptkbp:discontinued
|
in patients with severe heart failure
|
https://www.w3.org/2000/01/rdf-schema#label
|
Herceptin
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
HER2-positive gastric cancer
|
gptkbp:invention
|
gptkb:2019
|
gptkbp:is_monitored_by
|
cardiac function
infusion reactions
|
gptkbp:marketed_as
|
gptkb:Europe
gptkb:Australia
gptkb:Canada
gptkb:United_States
gptkb:trastuzumab
|
gptkbp:mechanism_of_action
|
HER2 receptor blockade
|
gptkbp:patient_population
|
gptkb:children
adults
|
gptkbp:price
|
high
|
gptkbp:provides_guidance_on
|
ASCO guidelines
NCCN guidelines
|
gptkbp:requires
|
available online
|
gptkbp:research_areas
|
gptkb:biotechnology
gptkb:pharmaceuticals
gptkb:immunotherapy
oncology
|
gptkbp:route_of_administration
|
intravenous
|
gptkbp:shelf_life
|
24 months
|
gptkbp:side_effect
|
headache
nausea
diarrhea
infusion reactions
cardiotoxicity
|
gptkbp:storage
|
2 to 8 ° C
|
gptkbp:targets
|
HER2 protein
|
gptkbp:used_for
|
treatment of breast cancer
treatment of gastric cancer
|
gptkbp:weight
|
148 k Da
|
gptkbp:bfsParent
|
gptkb:Genentech
|
gptkbp:bfsLayer
|
4
|